
The Zhitong Finance App learned that Jiuyuan Gene (02566) rose by more than 13%. As of press release, it had risen 13.42% to HK$4.31, with a turnover of HK$369,800.
According to the news, Jiuyuan Gene recently announced that the new drug clinical trial (IND) application for the Class 1 new drug JY54-2 injection developed independently by the company has been officially accepted by the Drug Evaluation Center (CDE) of the China Drug Administration. This IND application covers two indications, namely type 2 diabetes and weight management for people who are obese or overweight. The company plans to conduct a phase I clinical study of JY54-2 injection. The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of JY54-2 injection in test participants, and to provide a basis for its subsequent clinical development in the above two indications.
JY54-2 injection is a long-acting insulin analog independently developed by the company. This product is a next-generation pH-neutral and stable long-acting amylin analog, and has the potential to develop compound formulations with other metabolic drugs such as GLP-1 products. The company's pre-clinical trial data shows that in many pharmacodynamics and safety studies, JY54-2 injection showed excellent performance in all indicators. Based on its molecular design characteristics and mechanism of action analysis, JY54-2 injection is expected to support long-term dosing regimens and show differentiated clinical application potential in the field of weight management.